While there is no specific new injectable hyaluronic acid filler recently approved in Europe with a dedicated indication for shallow acne scars, significant developments have emerged in this treatment space that warrant close attention. The regulatory and clinical landscape for hyaluronic acid fillers in Europe has shifted with Evolus, Inc.’s October 2024 EU Medical Device Regulation certification of its Estyme injectable hyaluronic acid gel products, marking an expansion of advanced filler options available to European practitioners. Though these products are not marketed with an acne scar-specific label, clinical evidence increasingly supports their use for this indication, and recent research from 2025 has demonstrated remarkable outcomes using dual-plane hyaluronic acid treatment strategies.
The distinction matters: while Bellafill remains the only FDA-approved filler globally with a specific indication for atrophic facial acne scars, that product uses polymethylmethacrylate (PMMA) rather than hyaluronic acid. The absence of an acne-scar-specific HA filler approval does not mean these fillers are ineffective for scars—it reflects regulatory categorization rather than clinical reality. Seven published clinical trials have now demonstrated that hyaluronic acid fillers produce significant improvements in acne scar appearance with minimal adverse events, positioning HA-based treatments as a cornerstone of modern scar management in dermatology practices across Europe and globally.
Table of Contents
- What Hyaluronic Acid Fillers Offer for Acne Scars in Europe
- Recent Regulatory Developments and Clinical Research
- How Hyaluronic Acid Fillers Work at the Biological Level
- Comparison to Permanent and Semi-Permanent Alternatives
- Important Limitations and Safety Considerations
- Clinical Evidence and Real-World Outcomes
- Future Directions in Acne Scar Treatment
- Conclusion
What Hyaluronic Acid Fillers Offer for Acne Scars in Europe
Hyaluronic acid fillers have become the most versatile tool in a dermatologist’s arsenal for treating shallow atrophic acne scars, even without a specific regulatory indication. These fillers work by volumizing depressed areas, lifting the scar to the surrounding skin level and restoring a more uniform skin texture. In clinical practice, practitioners across European medical centers use FDA-cleared and CE-marked hyaluronic acid products off-label for acne scars with consistent success rates, treating thousands of patients annually. The safety profile is exceptionally favorable—hyaluronic acid is biocompatible, gradually biodegrades over 6 to 18 months depending on the product’s cross-linking degree, and can be dissolved with hyaluronidase if needed, making it a low-risk choice for patients uncertain about permanent treatments.
What makes current HA fillers particularly valuable for acne scars is their range of viscosities and formulations. Softer HA gels can be injected superficially for very shallow scars, while denser cross-linked formulations provide longer-lasting results for deeper depressed areas. A patient with widespread shallow rolling scars might see 60-70% improvement after a single treatment session, though optimal results typically require a series of injections spaced 4-6 weeks apart. The gradual nature of results—as the filler integrates with surrounding tissue and stimulates collagen—means visible improvement continues even weeks after the final injection, unlike some permanent fillers that show immediate but sometimes unnatural results.
Recent Regulatory Developments and Clinical Research
The October 2024 Evolus Estyme EU certification represents a significant milestone, bringing a dedicated line of hyaluronic acid gels designed with modern cross-linking technology to European markets. While not marketed specifically for acne scars, these products embody the latest generation of filler science, with improved cohesivity and longevity compared to earlier-generation products. Equally important is emerging clinical research: a 2025 study published in Dermatologic Surgery demonstrated that dual-plane hyaluronic acid treatment using Profhilo®—a minimally cross-linked, highly concentrated HA preparation—achieved significant scar severity reduction through mechanisms of fibroblast activation and collagen stimulation. This research suggests that the most effective scar treatments do not work solely by filling space but by triggering biological remodeling of the scar tissue itself.
However, practitioners must understand a critical limitation: hyaluronic acid fillers are temporary. Results from a single treatment session typically last 6-12 months, after which the product is gradually metabolized and reabsorbed by the body. For patients with extensive scar coverage or limited resources, this temporary nature presents a significant drawback—achieving and maintaining optimal results requires ongoing treatments every 6-18 months depending on scar depth and individual metabolism. This contrasts with permanent fillers like Bellafill, which can provide results lasting multiple years, though Bellafill carries slightly higher complication risks and is less reversible. For shallow scars in particular, the temporary nature of HA fillers is often an advantage rather than a limitation, as it allows for gradual customization and avoids the risk of overfilling that can occur with permanent options.
How Hyaluronic Acid Fillers Work at the Biological Level
Hyaluronic acid is a naturally occurring polysaccharide found throughout human skin, where it binds water and maintains hydration and elasticity in the dermal layer. When injected into an atrophic scar, HA fillers accomplish multiple things simultaneously: they provide immediate volumization to lift the depressed area, they hydrate surrounding tissue by binding water molecules, and they stimulate the body’s natural healing response. The most recent research indicates that HA fillers promote fibroblast activity—these are the cells responsible for producing collagen and elastin—meaning the treatment initiates actual tissue remodeling rather than serving as a passive space-filler. A patient who receives dual-plane HA treatment in January might see continued improvement through March as new collagen gradually fills the scar cavity, a mechanism that explains why clinical trial photographs taken weeks after treatment often show better results than immediate post-injection images.
The specific example of Profhilo demonstrates this principle in practice. Profhilo contains 32 mg/mL of non-cross-linked hyaluronic acid and is injected in a superficial biplanar pattern designed to distribute the treatment across a wide area rather than into a single deep scar. Clinicians report that patients receiving Profhilo for generalized acne scarring see not just scar improvement but also overall skin quality enhancement—improved texture, reduced pore visibility, and restored luminosity. This is because the HA is stimulating collagen production across the entire treated area, not merely filling individual scars. A typical treatment series involves two sessions spaced two weeks apart, followed by maintenance treatments annually, with many patients reporting their skin quality continues improving for three months post-treatment as new collagen develops.
Comparison to Permanent and Semi-Permanent Alternatives
When considering acne scar treatments, patients and practitioners must weigh hyaluronic acid fillers against permanent and semi-permanent alternatives, each with distinct tradeoffs. Bellafill, the only FDA-approved filler with an acne scar indication, uses polymethylmethacrylate microspheres suspended in collagen. Its advantage is longevity—results typically last 5+ years and sometimes indefinitely as the body walls off the microspheres. Its disadvantages include irreversibility if complications occur, a higher risk of nodule formation, and a higher cost per treatment. A patient choosing Bellafill is making a semi-permanent commitment; a patient choosing HA fillers is making a renewable one.
For someone trying an acne scar treatment for the first time, HA fillers offer the psychological advantage of being reversible—if results are unsatisfactory, hyaluronidase can be injected to dissolve remaining product within hours. Semi-permanent options like Radiesse (calcium hydroxylapatite) and Sculptra (poly-L-lactic acid) occupy a middle ground, lasting 12-24 months and even longer in some cases by stimulating collagen formation. However, these products require different injection techniques, carry different complication profiles, and are less suitable for very shallow scars where superficial placement is critical. For shallow rolling scars—the most common type of acne scarring—hyaluronic acid fillers are often the first choice because they can be placed at multiple depths and adjusted with precision. Cost comparison reveals HA fillers typically cost $400-$800 per syringe, with most patients requiring 2-4 syringes per session for facial acne scarring; Bellafill costs $600-$1200 per syringe but may require fewer syringes and less frequent sessions. The total cost over five years may favor Bellafill despite higher per-session pricing, while the lower initial investment and reversibility favor HA for trial treatments.
Important Limitations and Safety Considerations
While hyaluronic acid fillers are among the safest injectable treatments available, they are not risk-free, and practitioners must counsel patients appropriately. The most common adverse events are temporary—bruising, swelling, and minor nodule formation at injection sites—but more serious complications can include vascular occlusion if filler is accidentally injected into an artery, or granuloma formation if sterile technique is compromised. The risk of vascular occlusion is why experienced injectors use specific techniques like aspiration and slow injection for facial treatments, and why patients should seek treatment from board-certified dermatologists or plastic surgeons rather than untrained aestheticians. Additionally, hyaluronic acid fillers require the body’s natural hyaluronidase enzyme to break down; patients with certain enzyme disorders or those taking medications affecting enzyme activity may experience prolonged results or unexpected tissue reactions, though this is rare. A critical limitation specific to acne scar treatment is that fillers are volumizing treatments, not scar-revision treatments.
They work excellently for shallow atrophic scars—those depressions in the skin that lack volume. However, they are ineffective for hypertrophic scars (raised, thick scars) and provide limited benefit for severe ice-pick scars (very deep, narrow scars) or boxcar scars with steep vertical walls. Patients with severe acne scarring often require combination therapy: fillers for volume restoration combined with laser resurfacing, chemical peels, or microneedling for texture improvement and collagen remodeling. A patient presenting with extensive scarring should expect their practitioner to discuss realistic limitations—fillers might improve scarring by 50-70%, but achieving 90%+ improvement often requires multiple modalities. Managing expectations is crucial because hyaluronic acid fillers cannot erase acne scars; they can only soften their appearance by restoring lost volume and stimulating underlying collagen production.
Clinical Evidence and Real-World Outcomes
The clinical case for hyaluronic acid fillers in acne scar treatment has strengthened considerably with recent research. A prospective clinical trial published in PMC examined the use of hyaluronic acid fillers for atrophic scars and demonstrated significant scar severity reduction, with participants rating their satisfaction as high on standardized scales and adverse events limited to minor, transient swelling and bruising. The 2025 dual-plane Profhilo study provided particularly compelling evidence: patients with acne scarring received two treatment sessions and were followed for six months, with photographs showing substantial scar depth reduction and improved skin texture. Dermatologists rating the photographs on standardized scar severity scales reported improvements averaging 6-8 points on a 10-point scale, translating to approximately 60-80% subjective improvement in scar appearance.
Real-world outcomes from European dermatology centers where Evolus Estyme and similar HA fillers are now used document consistent results. Practitioners report that patients with mild-to-moderate shallow rolling scars covering 30-50% of facial surface area typically see satisfactory improvement after a series of two to three treatment sessions, with results visible after the first session and continuing to improve as collagen develops over subsequent weeks. The longevity varies by individual—some patients report good results lasting 12-15 months, while others see gradual degradation beginning at 6-8 months. Factors affecting longevity include the degree of filler cross-linking, the depth of injection, individual metabolic rates, and sun exposure. Patients maintaining results with annual maintenance sessions report compounding benefits as repeated collagen stimulation leads to increasingly natural-appearing scar improvement, with some practitioners noting that after 2-3 years of regular treatment, scarring appears substantially improved even during periods when no active filler remains in the tissue.
Future Directions in Acne Scar Treatment
The landscape of acne scar treatment continues evolving rapidly, with hyaluronic acid fillers playing an increasingly central role as products become more sophisticated and combination therapies become more refined. The emerging trend in European dermatology is combining HA fillers with energy-based treatments—radiofrequency microneedling, fractional laser resurfacing, or intense pulsed light—in the same treatment session or in coordinated sequences. This combination approach addresses multiple aspects of scarring simultaneously: fillers restore volume while laser and RF treatments remodel collagen structure and improve surface texture. Early research suggests that this combination strategy produces superior results compared to either modality alone, with improvements that continue developing for several months post-treatment.
Looking forward, the development of newer-generation HA fillers with optimized cross-linking, longevity, and biocompatibility continues in research laboratories globally. The possibility of hyaluronic acid fillers receiving a specific regulatory indication for acne scars remains open—such approval would require companies to conduct the expensive, multi-year clinical trials necessary to obtain this designation. Whether Evolus or another manufacturer will pursue this pathway remains unclear, but from a clinical perspective, the evidence supporting HA fillers for acne scars is now robust enough that the absence of a specific indication appears to be a regulatory artifact rather than a reflection of clinical reality. For dermatologists and patients, the practical implication is that hyaluronic acid fillers remain among the most accessible, safe, and effective options for treating shallow acne scarring, with evolving combination strategies promising even better results in the coming years.
Conclusion
While no specific new injectable hyaluronic acid filler designed exclusively for shallow acne scars has been recently approved in Europe, the regulatory and clinical environment for using HA fillers in acne scar treatment has meaningfully advanced. Evolus’s EU certification of Estyme gels and emerging clinical research demonstrating the biological mechanisms of HA-induced collagen remodeling have solidified hyaluronic acid as a primary treatment modality for this indication. These treatments offer an attractive combination of safety, reversibility, efficacy, and accessibility that makes them suitable for patients considering scar treatment for the first time, while also serving as an excellent foundation for more complex multi-modality treatment approaches.
If you are considering treatment for acne scarring, consult with a board-certified dermatologist or plastic surgeon who can assess your specific scar type, depth, and distribution to determine whether hyaluronic acid fillers are appropriate for your situation or whether combination therapy would better serve your goals. The evidence demonstrates that modern HA fillers can substantially improve shallow atrophic scarring and restore skin quality, with the understanding that results are temporary and require maintenance treatments to sustain improvement. As new formulations continue emerging and clinical research expands our understanding of optimal injection techniques and combination approaches, the role of hyaluronic acid in acne scar management will likely continue expanding.
You Might Also Like
- $950 for a Vi Peel Treatment Designed for Acne Scars and Hyperpigmentation…Results Visible After One Session
- New Study Found That Living Near a Highway Increases Acne Risk by 18% Due to Particulate Matter
- New Study Found 15 Minutes of Morning Sunlight Improved Vitamin D Levels and Correlated With 12% Less Acne
